24th week of 2019 has $mnkd 5 yr old Afrezza scripts at New 333 Rxx 397 Label clearly informs : AFREZZA is not a substitute for long-acting insulin. Causes a decline in lung function over time as measured by FEV #Diabetes#T1D#T2D#LiveLife#bloodsugar#insulin $LLY $NOVO $SNY
$mnkd $novo how many more years until #afrezza completes its P2 study?
Novo Nordisk’s Victoza secures FDA paediatric approval for type 2 diabetes https://t.co/w2k0iS26nO via @Pharmaceutical Business review
@SEC_Enforcement watch $MNKD for possible #REAL_TIME stock pumper manipulation. @US_FDA#FDA Office of Prescription Drug Promotion watch $mnkd social media including facebook groups for false and misleading claims denying risks and dangers of Black Box afrezza. $SNY $LLY $NOVO
The $mnkd FDA label for Afrezza tells the truth plain and simple without cherry picking - "
"provided less HbA1c reduction than insulin aspart, and the difference was statistically significant. More subjects in the insulin aspart group achieved the HbA1c target of ≤7. "
$arna Revs from only drug can't pay daily operations, Executive salaries, pipeline studies, patent case legal fees, free shares to insiders. Dilution seems inevitable #stocks#pharma#biotech#biotechnology
$12 Mil up front from a $50M Boston start-up for 2 drugs $arna has been hyping for years. The $12M matches the partial settlement they owe for the Class Action suit. LOL Things that make you go Hmm #stocks#biotech#pharma $XBI